Novartis (NVS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.46
- Estimate
- $2.24
- Surprise
- +9.7%
- Revenue (period 2026-09-30)
- $15.03B
- Score at report (before → after)
- 5.1 → 5.1/10
Revenue source: yfinance_provisional (provisional — SEC XBRL not yet filed for this period).
How the report landed
Novartis (NVS) beat the $2.24 estimate with adjusted EPS of $2.46 — a clear 9.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.1/10) to Sell at 5.1/10 after the report.
Coverage in the report window
- RBC Raises Price Target on Novartis to CHF130 — fiscal.ai, 2026-10-28
Where TrendMatrix's rating stands now
TrendMatrix currently rates NVS Sell at 4.9/10.
3 of the last 4 quarters beat the estimate; this quarter's +9.7% surprise compares with a +5.8% four-quarter average. Next scheduled report: 2027-02-03.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Analyst target reached - limited upside remaining
- Leverage penalty (D/E 1.3): -0.5
- Weak overall score: 4.9/10
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $156.08
- Stop
- $150.08
The stock trades at 29.8× trailing but 15.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 73 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
NVS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $294.78B
- P/E (fwd)
- 15.8
- P/E (ttm)
- 29.8
- 52-week range
- $121.57–$170.46
- Off 52-week high
- 8.4%
- RSI (14)
- 73
- Volume vs avg
- 0.97×
- Score today
- 4.9/10